Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms

• Main Authors: Katharina Luise Schneider (Author), Melanie Kunst (Author), Ann-Kristin Leuchs (Author), Miriam Böhme (Author), Klaus Weckbecker (Author), Kathrin Kastenmüller (Author), Markus Bleckwenn (Author), Stefan Holdenrieder (Author), Christoph Coch (Author), Gunther Hartmann (Author), Julia Carolin Stingl (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundDose requirements of vitamin K antagonists are associated with CYP2C9 and VKORC1, but, compared to warfarin, less data is available about phenprocoumon. Furthermore, the effects on dose stability and anticoagulation quality are still unclear.MethodsAim was to scrutinize phenprocoumon dose...